Preliminary Agenda Now Available

Today, biospecimen collections are used by multiple research groups for various research aims, from basic research through clinical trials. Useful biosamples must be collected to maintain their molecular integrity for specific (or unknown) downstream analysis. Thus, the proper collection, processing, storage and tracking of biospecimens are critical components allowing researchers to better link molecular and clinical information. Cambridge Healthtech Institute’s 8th International Leaders in Biobanking Congress: Applying Biospecimen Science to Advance Biomedical Research addresses biospecimen science, management, and applications, bringing together biomedical and biopharmaceutical researchers, regulators, biorepository managers and practitioners to investigate the best strategies for effective use of biospecimens within today’s cutting-edge biomedical research.


KEYNOTE PRESENTATION
The NIH Precision Medicine Initiative: The Potential of a Million

Josephine P. Briggs, M.D., Interim Director, Precision Medicine Initiative Cohort and Director, National Center for Complementary and Integrative Health (NCCIH), National Institutes of Health


It Takes a Village

Biobanking in the 21st Century: Opportunities and Challenges

Stella Somiari, Ph.D., Senior Director, Biobank and Biospecimen Science Research, Windber Research Institute

Modern Biorepository Informatics Infrastructure: A Data-Driven, Service-Oriented Modular Approach to Operation and Discovery

Alex S. Felmeister, Supervisor, Data Integration – Enterprise Informatics, Translational Informatics Unit, Department of Biomedical and Health Informatics, The Children’s Hospital of Philadelphia

Investigator Experiences and Attitudes about Research with Biospecimens

Suzanne M. Rivera, Ph.D., Vice President, Research and Technology Management, Case Western Reserve University

The Importance of Centralized and Harmonized Biobanking to Support Precision Medicine Initiatives across Government, Academic and Industrial Initiatives

Andrew Brooks, Ph.D., COO, RUCDR Infinite Biologics; Associate Professor, Genetics, Rutgers University


Biospecimens Link Cancer Molecular Markers to Clinical Information

ZNF Hypermethylation from ctDNA in Cancer

Laura Elnitski, Ph.D., Senior Investigator & Translational and Functional Genomics Branch Head, Genomic Functional Analysis Section, National Human Genome Research Institute (NHGRI), National Institutes of Health

Circulating Nucleic Acids in Cancer Treatment Monitoring

Anton Wellstein, M.D., Ph.D., Professor, Oncology, Pharmacology and Medicine; Associate Director, Basic Science, Lombardi Comprehensive Cancer Center, Georgetown University Medical School

Precision Medicine Begins with Biospecimens

Michael Roehrl, M.D., Ph.D., Director, Precision Pathology Biobanking Center, Memorial Sloan Kettering Cancer Center


Biomarkers from Biobanks

Assessing the Scientific Utility of a Biospecimen Collection: The NHLBI Approach

Elizabeth Wagner, Scientific Program Coordinator, Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health

A Large-Scale Postmortem Biospecimen Collection for Studying Genetic Variation: The Genotype-Tissue Expression (GTEx) Project

Abhi Rao, Ph.D., Biospecimen Technology Program Manager, Biorepositories and Biospecimen Research Branch (BBRB), National Cancer Institute, National Institutes of Health

BioProcessingSolutionsGaining Scientific insights through the Integration of Pharmacogenomics Analysis with Sample Management

Peter Shaw, Ph.D., Head, Clinical Pharmacogenomics , Merck & Co.

Andrew Brooks, Ph.D., COO & Director, Technology Development, RUCDR Infinite Biologics, Rutgers University


Case Study Co-Presentation

BIOspecimen STOrage and REquest: How BIOSTORE & Biorepository at BMS Empowers Scientists to Exploit Our Sample Assets for Research

Karl Kammerhoff, MBA, Senior Operations Analyst, BMS Biorepository, Clinical Translational Technologies & Operations, Exploratory Clinical & Translational Research, Bristol-Myers Squibb
Christopher Nalbone, Business Capability Manager, Clinical & Translational R&D IT, Bristol Myers-Squibb
Erin Daniels, MSc, Research Scientist, Clinical Pharmacogenomics, Bristol Myers-Squibb


Fit-for-Purpose Biopreservation

DNA Stability Study: Assessing DNA at Varied Temperatures for Long-Term Storage Solutions

L. Scott Clark, Ph.D., Vice President, Biopharma Scientific Affairs and Global Quality Assurance, Cancer Genetics, Inc.




For more details on the conference, please contact:
Mary Ann Brown
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: (+1) 781-972-5497

Email: mabrown@healthtech.com

For sponsorship and exhibit sales information, please contact:
Carolyn Benton
Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email:
cbenton@healthtech.com